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γ-H2AX and 53BP1 fociTelomerase is mainly active in human tumor cells, which provides an opportunity for a therapeutic window
on telomerase targeting. We sought to evaluate the potential of the thio-phosphoramidate oligonucleotide
inhibitor of telomerase, imetelstat, as a drug candidate for treatment of esophageal cancer. Our results
showed that imetelstat inhibited telomerase activity in a dose-dependent manner in esophageal cancer
cells. After only 1 week of imetelstat treatment, a reduction of colony formation ability of esophageal cancer
cells was observed. Furthermore, long-term treatment with imetelstat decreased cell growth of esophageal
cancer cells with different kinetics regarding telomere lengths. Short-term imetelstat treatment also increased
γ-H2AX and 53BP1 foci staining in the esophageal cancer cell lines indicating a possible induction of DNA double
strand breaks (DSBs). We also found that pre-treatment with imetelstat led to increased number and size of
53BP1 foci after ionizing radiation. The increase of 53BP1 foci number was especially pronounced during the
ﬁrst 1 h of repair whereas the increase of foci size was prominent later on. This study supports the potential of
imetelstat as a therapeutic agent for the treatment of esophageal cancer.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Telomerase is a reverse transcriptase involved in the unlimited
growth of tumor cells. It synthesize telomere repeats onto chromosomal
ends, thus compensating for telomere shortening during the DNA repli-
cation cycle [1]. Telomerase is repressed in the majority of somatic cells
but activated in approximately 85% of all human cancer types [2]. Thus,
telomerase represents an attractive target to new forms of cancer therapy
and several studies have supported that rationale [3]. Telomerase is a
complex multisubunit ribonucleoprotein enzyme in which the minimal
catalytic core includes thehTERTprotein and the telomerase RNAcompo-
nent (hTRor hTERC). hTR functions as the template for the enzyme to add
the telomere repeats at the chromosome end [4]. During the latest years
several telomerase-based anticancer approaches have been studied
i.e. telomerase inhibitors targeting hTERT or hTR, telomere-disruptingliated The Second Hospital of
.: +86 2583626181; fax: +86
l rights reserved.agents, hTERT promoter-driven gene therapy, hTERT immunotherapy
as well as blocking telomerase expression or biogenesis [3].
Imetelstat is a potent telomerase inhibitor targeting the template
region of hTR and acting as an oligonucletide template antagonist. It
represents the latest generation of modiﬁed oligonucleotides and
contains a 13-mer oligonucleotide thio-phosphoramidate and a lipid
group [5]. The presence of the covalently conjugated lipid group pro-
vides high cellular uptake and bio-availability. Furthermore, the thio-
phosphoramidate internucleoside linkages in imetelstat provides
for high thermodynamic stability of its complex with the targeted
hTR and long half-life [5,6]. Imetelstat has been shown to cause
telomere length dependent but also telomere length independent
effects in a large variety of tumors in vitro [7]. Imetelstat has also
entered clinical trials for multiple tumor types; chronic lymphocyt-
ic leukemia, multiple myeloma, lung, breast and advanced tumors
[6].
Esophageal carcinoma is the seventh most common cause of
cancer-related death in the Western world and has a poor prognosis
[8]. Standard treatments for these patients include surgery, radiation
and chemotherapy. Because of the dismal prognosis new anti-cancer
strategies are highly warranted. The aim of the current study was to
evaluate the effects of telomerase-based therapy (imetelstat) in
esophageal carcinoma cell lines.
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2.1. Cell culturing and counting
The human ESCC (esophageal squamous cell carcinoma) cell
Kyse410 and Kyse520 (Deutsche Sammlung von Mikroorganismen
und Zellkulturen GmbH, Braunschweig, Germany) were cultivated
in RPMI-1640 medium, supplemented with 10% fetal bovine serum
(FBS), 2 mM L-Glutamine, 50 U Penicillin and 50 μg Streptomycin/ml
(Sigma-Aldrich, St Louis, MO, USA). Cells were split twice a week by in-
cubation in 13–20 μl/cm2 5xTrypsin-EDTA Solution (Sigma-Aldrich) in
37 °C until detachment from the surface. Cell counting was performed
using a Coulter® Z2 Particle count and size analyzer. For long term
cell culture studies, Kyse410 and Kyse520 cells were given imetelstat
(1 μM) (Geron, CA, USA) or its sense control oligonucleotide every 3
or 4 days in 3-cm Petri dish. The cells were counted every week to de-
termine population doublings during course of 30 weeks of treatment.
Population doublings were calculated as log (the number of cells col-
lected/the number of cells plated)/log 2 [9].2.2. Telomere real time PCR
DNAwas extracted from cell pellets using the Nucleon extraction and
puriﬁcation kit (AmershamBiosciences). Quantitative real-time PCRwas
used to measure relative telomere length. The telomeres and the single
copy gene β2-globin were ampliﬁed on separate plats in all samples
and in an internal reference cell line DNA (CCRF-CEM). All samples
were compared to the reference DNA to give a relative telomere value.
The ΔΔCt method was used for calculation of RTL values and a standard
curve was created in each PCR run to monitor the PCR efﬁciency. A
detailed protocol has previously been published [10]. To be able to
convert relative telomere length to kb, telomere length by quantitative
PCR and by southern blot have beenmeasured on 44 CLL patients giving
the formula y=3.27∗X+2.98.Table 1
Telomere length (Kb) of esophageal cancer cell lines.2.3. Telomerase activity assay
Telomerase activity from cell extracts was analyzed using a PCR
based telomeric repeat ampliﬁcation protocol (TRAP) assay described
by Kim et al. [11]. Kyse410 and Kyse520 cells were pelleted and lysed
for 30 min in 200 μl of CHAPS lysis buffer/106 cells. Protein content
was determined using the BCA protein assay reagent kit (Pierce chemi-
cal). Same amount of proteins was used in each reaction. Samples were
mixed with TRAPeze kit reagents (Chemicon) according to the
manufacture's instruction, and a combined elongation and ampliﬁcation
reaction was performed in a GeneAMP PCR system 9700 (Applied
Biosystem). After 30 min incubation at 30 °C, the reaction mixture was
heated to 94 °C for 5 min and then subjected to 33 cycles of 94 °C for
30 s and 55 °C for 30 s. Reaction mixtures were size-fractionated by
electrophoresis in a 10% non-denaturing polyacrylamide gel and stained
with SYBR Green 1 dye (Invitrogene). Gels were photographed using the
Gel DocXR photo system (Bio-Rad) and analyzed with the Image Lab
software (Bio-Rad). Relative telomerase activity of each extract was de-
termined by calculating the ratio of the entire telomerase ladder to the
signal of the internal control.Sample Relative telomere length Kb (y=3.27 * X+2,98)
Kyse30 0.46 4.48
Kyse70 0.33 4.06
Kyse140 0.19 3.60
Kyse150 0.42 4.35
Kyse180 0.38 4.22
Kyse410 1.02 6.32
Kyse450 0.72 5.33
Kyse510 0.3 3.96
Kyse520 0.16 3.502.4. Clonal efﬁciency assay
Kyse410 and Kyse520 cells were trypsinized and plated onto 10-cm
tissue culture dishes at various cell densities for clonogenic cell survival.
Cells were incubated for 10–11 days, ﬁxed with ethanol and stained by
Giemsa. Clonogenic cells were deﬁned as those able to form a colony of
at least 50 cells.2.5. Immunoﬂuorescent staining
Kyse410 and Kyse520 cells were grown on coverslips overnight and
then treatedwith 10 μMimetelstat for 3 days. Cellswere irradiatedwith
2 Gy. At a speciﬁc time point, cells were ﬁxed inmethanol at−20 °C for
20 min andpermeabilized in cold acetone for 10 s. Coverslips were then
blocked with 10% FBS at room temperature for 1 h, incubated with
primary antibodies speciﬁc for 53BP1 (1:100, Bethyl Laboratories)
and γH2AX (1:100, Upstate), followed by incubation with ﬂuorescent
secondary antibodies, goat anti-rabbit Alexa480 and goat anti-mouse
Alexa555 (1:100, Molecular Probes). The cell nuclei were stained with
DAPI dilactate (0.4 μg/ml, Molecular Probes). Coverslips were air dried
and coverslips were mounted on the slides using Vectashield mounting
medium H-1000 (Vector Laboratories).
2.6. Image acquisition and digital image analysis
Images of the immunostainings were acquired with a Spot Insight
CCD-camera (Diagnostic Instruments) connected to a Nikon Eclipse
E400 microscope equipped with G-2A, FITC and UV-2A ﬁlters (Nikon
Corporation). All images were acquired at 40× magniﬁcation using a
40× objective. The number of 53BP1 foci per cell was determined by
an image analysis procedure based on laplace-ﬁltering followed by seg-
mentation and labeling algorithms [12,13]. A total of 8000 cells from
three repeated stainings were included in the analysis. Since edge
detecting laplace ﬁlters potentially alter the shape of a detected struc-
ture, foci size was measured in a separate procedure where the laplace
ﬁlter were excluded. All analyses were manually surveilled to conﬁrm
that the detected foci numbers and sizes corresponded to the visual in-
terpretation of the staining. All digital image analysis algorithms were
implemented in Java™ and the Java Advanced Imaging (JAI) platform.
3. Results
3.1. Imetelstat inhibits telomerase activity in esophageal cancer cells
To study the effects of the telomerase antagonist imetelstat we
selected two cell lines from a panel of esophageal carcinoma cell
lines that had undergone telomere length analysis by a real-time
based method. As can be seen in Table 1 the telomere length varied
between 3.5 and 6.3 Kb among the different esophageal cancer cell
lines. For further experiments we selected to study the cell lines
with the shortest telomeres (Kyse520) and the longest telomeres
(Kyse410). To evaluate the effect of imetelstat on telomerase activity,
the esophageal cancer cells were treated with various concentrations
for 72 h. As shown in Fig. 1, TRAP analysis revealed that imetelstat
inhibited telomerase activity in a dose-dependent manner. Compared
to 10 μM sense control treatment, telomerase activity was signiﬁcantly
inhibited by 1 μM imetelstat, the inhibition rate was 67% for Kyse410
(Fig. 1A) and 90% for Kyse520 (Fig. 1B). At 10 μM imetelstat treatment,
the telomerase activity was inhibited by 71% for Kyse410 and 99% for
Kyse520, respectively. No inhibition of telomerase activity was seen
when the cells were treated with 10 μM sense control.
Fig. 1. Inhibition of telomerase activity of Kyse410 (A) and Kyse520 (B) cells after treatment with different doses of imetelstat and sense control oligonucleotide for 72 h. The experiment
has been repeated three times. A representative ﬁgure is shown.
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To examine the effect of imetelstat on cellular growth, Kyse410 and
Kyse520 were treated with 1 μM imetelstat every 3 days and the cells
were collected and counted each week. Addition of imetelstat to
Kyse410 (long telomeres) caused a decrease in cell growth already
after 3–4 weeks (Fig. 2A). Interestingly, the growth inhibition did not
occur earlier in the cell line Kyse520 with short telomeres (Fig. 2B).
Thereafter, a continuous decrease in cell growth was observed and at
the end of the experiment the imetelstat treated cells had undergone
20 fewer population doublings compared to sense control in Kyse410
(Fig. 2A). Addition of imetelstat to Kyse520 (short telomeres) resulted
in decrease in cell growth after approximately 5–6 weeks. Thereafter,
the decrease in cell growth became more pronounced compared toFig. 2. Long-term treatment of Kyse410 (A) and Kyse520 (B) cells with 1 μMof imetelstat
and sense control. Imetelstat and sense were added to the cell culture medium every
3 days. The cells were subcultured every week and cell numbers were counted.Kyse410 (Fig. 2B). After 30 weeks the imetelstat-treated cells had un-
dergone 36 fewer population doublings compared to sense control.
Thus in the cell line with short telomeres the slowing of cell growth
was more prominent and at the end part of the experiments there
was an almost complete abrogation of growth. No effect on population
doubling was observed by the sense control compared to vehicle PBS.
3.3. Treatment with imetelstat results in loss of colony formation ability
To study if imetelstat decreases colony formation and the impact of
pre-treatment for different time periods we performed clonal efﬁciency
assay. We observed an approximately 60% reduction in colony forma-
tion ability after 1 week of pre-treatment with imetelstat (1 μM, two
doses for 1 week) in both Kyse410 (Fig. 3A) and Kyse520 (Fig. 3B).
This short-term effect of imetelstat may be related to unknown effects
of imetelstat that are independent of telomere dysfunction. Long-term
pre-treatment with imetelstat for different time periods before the
performance of clonal efﬁciency assay caused a continuously more
pronounced reduction of colonies in both Kyse410 and Kyse520.
3.4. Imetelstat increases formation of radiation-induced 53BP1 and
γ-H2AX foci
To investigate whether there may be a potential function of telome-
rase inhibition in the DNA damage response after ionizing radiation we
investigated the formation of γ-H2AX and 53BP1 foci, which are indica-
tors of radiation-induced DNA double strand breaks (DSBs). Fig. 4 dem-
onstrates that 53BP1 foci could be clearly detected and co-localized
with γ-H2AX in irradiated cells pre-treated with imetelstat. However,
53BP1 foci staining was superior compared to γ-H2AX in terms of con-
trast and signal to noise ratio. For further analyses we used 53BP1 foci
staining. The average number of 53BP1 foci per cell was assessed begin-
ning at 30 min after 2 Gy and thereafter at 1 h, 2 h and 24 h. As shown in
Fig. 5A, both Kyse410 and Kyse520 cells showed a similar pattern with a
peak of 53BP1 foci at 1 h after 2 Gy irradiation followed by a decrease.
For Kyse410, the average number of 53BP1 foci per cell in cultures re-
ceiving the combined imetelstat/radiation treatment was signiﬁcantly
higher (pb0.0001) compared to cultures treated with sense/radiation
at time point 0.5 h after 2 Gy irradiation. At time point 2 h and 24 h,
the p values were 0.055 and 0.066 respectively, thus on the border line
of signiﬁcance. For Kyse520, the average number of 53BP1 foci per cell
in cells receiving combined imetelstat/radiation treatment was sig-
niﬁcantly higher than cells treated with sense/radiation at 0.5 h
(p=0.0015) and 24 h (p=0.0088) after 2 Gy irradiation. Furthermore,
treatment with 10 μM imetelstat for 3 days without radiation also
resulted in signiﬁcant induction of 53BP1 foci compared to sense treat-
ment for both Kyse410 (p=0.0078) and Kyse520 (p=0.0002) cells.
Thus imetelstat per se is able to induce 53BP1 foci after short-term
Fig. 3. Colony formation assay of imetelstat pre-treated esophageal cancer cells com-
pared to sense control pre-treated cancer cells. Pretreated Kyse410 and Kyse520 cells
were seeded in 10-cm Petri dishes without further addition of imetelstat and sense.
After 10–11 days, colonies were ﬁxed and stained by Giemsa. A, Colonies formed by
Kyse410 after pre-treatment with 1 μM imetelstat. B, Colonies formed by Kyse520
after pre-treatment with 1 μM imetelstat. Results are average of three repeats.
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53BP1 foci sizes were larger in imetelstat/radiation treated cells com-
pared to sense/radiation treated cells in both Kyse410 and Kyse520 at
repair time points 2 h and 24 h (pb0.05).Fig. 4. Representative γH2AX (red) and 53BP1 (green) foci staining 24 h after ionizing radiation
nuclei staining. Lane A: Kyse410 cells pre-treated with 10 μM imetelstat for 3 days. Lane B
pre-treated with 10 μM imetelstat for 3 days. Lane D: Kyse520 cells pre-treated with 10 μM se4. Discussion
Telomerase is active in the majority of cancer cells but absent in al-
most all normal somatic cells, and recently also tumor-initiating cells
have been reported to be telomerase positive [11,14–16]. This discrepan-
cy between cancer and normal cells provides a substantial therapeutic
window for telomerase inhibition-based treatment. Thus telomerase
is an attractive target for cancer therapy and several strategies have
been applied for targeting telomerase [17]. Imetelstat is an oligomer an-
tagonist that has high afﬁnity to the template region of telomerase RNA
and prevents assembly of an active telomerase enzyme [18]. This leads
to effective telomerase inhibition and progressive telomere shortening
in tumor cells.
In the present study,we investigated the in vitro effects of imetelstat
in esophageal cancer as a potential therapeutic modality. Administra-
tion of imetelstatwas shown to inhibit telomerase activity in esophage-
al carcinoma cell lines with different mean telomere lengths (Fig. 1).
Long-term treatment with imetelstat resulted in decreased growth
rate of esophageal cancer cells as determined by population doublings.
At the end part of the experiments therewas an almost total growth ab-
rogation in the cell line (Kyse520) with the shortest telomere length.
Notable, in both Kyse410 and Kyse520 cells the decreased growth rate
was observed already after a few weeks, thus providing support for
telomere length-independent effects mediated by imetelstat. Further-
more, imetelstat treatment decreased colony formation capacity within
1 week as shown in Fig. 3, thus representing another short-term effect.
These anti-colony forming effects likely are not caused by signiﬁcant
shortening of telomeres, since it is observed as early as after 1 week of
treatment by more than 50%. The mechanism behind that effect might
be explained by a direct binding to the telomerase enzyme and inhibition
of telomerase by imetelstat. Interestingly, long-term imetelstat treatment
caused a successive impaired colony formation capacitywith time in both
cell lines, again providing support for potential multi factorial mecha-
nisms of imetelstat.
Telomeres are formed by repeats of the TTAGGG sequence and serve
as protective caps of linear eukaryotic chromosomes. Loss of telomere
function or erosion of telomeres will lead to genetic instability, senes-
cence or apoptosis. In normal somatic human cells the progressive short-
ening of telomeres function as a mitotic clock that triggers replicativewith 2 Gy.γH2AX (red) and 53BP1 (green) foci stainingweremerged togetherwith DAPI
: Kyse410 cells pre-treated with 10 μM sense control for 3 days. Lane C: Kyse520 cells
nse control for 3 days.
Fig. 5. (A) Imetelstat increases the formation of radiation-induced 53BP1 foci. Kyse410 and Kyse520 cells growing on cover slips in 3.5 cm dishes were treated with 10 μM imetelstat
or sense control for 72 h, then radiated and ﬁxed at speciﬁc time points for analysis of 53BP1 foci formation by using immunoﬂuorescence microscopy. Statistical signiﬁcance was
established by t test. Bars mean SEM. (B) Aligned dot plot shows the 53BP1 foci size (μm2) at 2 h and 24 h repair time. The esophageal cancer cells was pre-treated with the telomerase
inhibitor imetelstat or sense control and exposed to radiation with 2 Gy. The line across the aligned dots indicates mean value of 53BP1 foci size. Nonparametric Mann–Whitney test
shows that the difference of 53BP1 foci size between imetelstat and sense treated group is statistically signiﬁcant (pb0.05).
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reﬂect a DNAdamage checkpoint responsewhich is directly connected to
uncapped telomeres at chromosome ends [20]. In the majority of malig-
nant cells reactivation of telomerase counteracts telomere shortening,
overcomes senescence and leads to immortalization [11]. On the other
hand, telomerase has also been assigned to exert pro-survival functions,unrelated to telomere length maintenance [21,22]. Short-term suppres-
sion of hTERT expression has been reported to be associatedwith abroga-
tion of DNA-damage repair [23] and changes in hTR levels exert effects on
the DNA-damage check point response [24]. With that background we
wanted to clarify whether short-term inhibition of telomerase with
imetelstat affects the DNA damage response and investigated markers
2135X. Wu et al. / Biochimica et Biophysica Acta 1823 (2012) 2130–2135for DSBs. Interestingly, an increased number of 53BP1 foci was observed
after treatment with imetelstat only for 3 days, indicating an increase in
DSBs (Fig. 5A). These data support the notion that telomerase is involved
in DNA damage response and that inhibition of telomerase with
imetelstat caused an increase of DSBs in a telomere length-independent
fashion.
Several studies have provided a link between radiosensitivity,
DNA damage response and telomerase. Wong et al. showed that telo-
mere dysfunction in telomerase deﬁcient mouse developed a radio-
sensitivity syndrome, which correlated with delayed DNA break
repair [25]. In addition, long-term treatment with imetelstat led to
progressive reduction in telomere length and sensitized breast cancer
cells to radiation determined by survival colony formation assay [26].
We further addressed the issue whether short-term treatment sensi-
tize esophageal cancer cells to induce radiation mediated DSBs. When
cells were treated with a combination of imetelstat and radiation, we
observed an early synergistic increase and prolonged higher expres-
sion of DSB foci compared to cells treated with sense/radiation com-
bination. These observations are consistent with a previous report
that demonstrated increased levels of phosphorylated 53BP1 and
H2AX in irradiated glioblastoma tumor-initiating cells pre-treated
with imetelstat for 72 h [27]. Interestingly, we also observed that
the 53BP1 foci size increased after radiation and the combination of
imetelstat/radiation resulted in larger 53BP1 foci sizes in cells, espe-
cially at the late repair time point 24 h, compared to sense/radiation
treated cells (Fig. 5B). It is known that upon radiation, activated
ataxia-telangiectasia mutated (ATM) proteins phosphorylate H2AX,
which subsequently recruits various downstream proteins like
53BP1, NBS1, MDC1 and MRE11 to form ionizing radiation-induced
foci [28,29]. It has been suggested that large persistent DSB-foci
could signal an ampliﬁed DNA-damage response that ensures a sufﬁ-
cient checkpoint-response in cells with a limited amount of DNA-
damage [30,31]. This suggests that the increased foci size in imetelstat
treated cells could be interpreted as an increase in damage severity or
impaired repair capacity. It has also been reported that radiation tran-
siently up-regulates telomerase activity via the Ras/phosphatidylinositol
3-kinase/Akt pathway [32]. In this regard, it may be speculated that the
transient up-regulation of telomerase in cells confers a stress response
and an attempt to protect against DNA damage and the pre-treatment
with imetelstat abrogate this effect. However, the connection between
the short-term inhibition of telomerase activity and DNA damage re-
sponse reported in the present study needs further investigation. Besides
combination of imetelstat with radiation another possible option will be
to combine imetelstat with chemotherapy or other types of anti-cancer
therapies.
In conclusion, the telomerase antagonist imetelstat inhibits telome-
rase activity in esophageal cancer cells and decreases proliferation and
colony formation ability. Short-term inhibition of telomerase activity led
to an increase of 53BP1 foci indicating an induction of DSBs. Furthermore,
the fraction and size of radiation induced 53BP1 foci were increased after
pre-treatment with imetelstat providing support of that telomerase inhi-
bition modulates the DNA damage response after radiation.References
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